- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06869759
"Effectiveness of Community Health Workers in Breast Cancer Prevention in Jumla: a Cluster Randomized Trials
Effectiveness of Community Health Workers Induced Prevention of Breast Cancer by Community Health Promotion and Education Implementation Strategies in Jumla - a Cluster Randomised Controlled Trial
Breast cancer is the second most prevalent cancer among Nepali females, accounting for 17.1% of cases and 7.7% of female cancer-related deaths. It is more common in younger, premenopausal women, often diagnosed at advanced stages. Raising awareness through community education is crucial for promoting breast cancer screening, particularly in low-resource settings like Nepal, where clinical breast exams are essential early detection tools. Integrating breast cancer education into the health system can enhance knowledge, encourage screening, and promote healthy behaviors for prevention. Early detection significantly improves treatment outcomes and survival rates.
In remote areas, limited access to advanced detection technologies makes breast self-examination (BSE) the most feasible and cost-effective method, particularly in Jumla. This study evaluates the effectiveness of community health worker-led breast cancer prevention through health promotion and education strategies. It follows PROCTOR's framework and the Health Belief Model (HBM) A mixed-methods design will be employed, incorporating an embedded implementation science approach, a cluster-randomized trial, and mixed-method research. The study population includes married women of Jumla, female community health volunteers (FCHVs), and auxiliary nurse midwives (ANMs). Exclusion criteria include married women ≥20 years old with existing cases of cancer, pregnant or lactating women, FCHVs unable to acquire BSE skills, and untrained ANMs. The sample consists of 90 participants in both intervention and control groups.
Acceptability, Appropriateness, and Feasibility will be assessed using the Acceptability of Intervention Measure (AIM) tool. SOP-based checklists will evaluate fidelity, while FGDs and KIIs will collect qualitative data. Quantitative data will be analyzed using frequency, percentage, mean, and standard deviation. A paired t-test and mixed-effect linear regression will assess effectiveness, while qualitative data will undergo thematic analysis. Findings will be reported per CONSORT guidelines.
Ethical approval will be obtained from the Nepal Health Research Council. Expected outcomes include improved breast cancer knowledge, perception, and screening intention, leading to early detection and reduced prevalence. However, selection bias in cluster trials may limit generalizability.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Karnali
-
Jumla, Karnali, Nepal
- Karnali Academy of Health Sciences, Jumla, Karnali, Nepal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Married women >= 20 years of age group women of CNMP Jumla,
- FCHV, those who can read, write, and understand, and
- ANM
Exclusion Criteria:
- Married women >= 20 years age group women who had a positive existing case,
- Pregnant and lactating women of CNMP Jumla,
- FCHV those who cannot acquire the minimum skill of breast self-examination,
- ANM who untrained for BSE.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Arm
Arm Description: Clusters will be based on the municipality's wards, to measure the effectiveness of implementation outcomes.
There are nine wards in the study site, three of which will be selected for intervention group.
Thirty samples will be obtained from each randomly selected cluster of intervention.
|
Firstly, three broad strategies will be implemented in the intervention arm (use of advisory boards, sensitization, and linkage to care).
The advisory board meetings will be held every month to discuss the progress and receive their feedback.
Secondly, orientation and capacity building will be done by onsite coaching to community health workers at the health facility level on BSE.
Those trained health workers will frequently capacitate FCHVs during monthly meetings.
Then, FCHV will visit the community to be aware of BSE as well as they will be involved in a stigma reduction campaign.
Sensitization to FCHVs through orientation and capacity building by providing 3 batch training to selected 3 wards, then FCHVs aware and practice the skills of BSE to the recruited participants during home visit and Thirdly, the suspected and identified cases will be linked by strengthening the referral mechanism of the health system and CHWs reminders for follow-up to cases.
|
|
No Intervention: Control Arm
Arm Description: Thirty samples will be obtained from each randomly selected cluster of control group who would not be given any intervention, this group consist of 90 participants.
The usual work done by the health system of Nepal (i.e: PEN package); after the end line, will also capacitate the control group by radio jingle after seven month of intervention.
A mass campaign will be conducted on the process and importance of BSE by airing a radio jingle on local FM.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The implementation outcome will be measured by: Acceptability (attitude and perception of women toward BSE and satisfaction levels of the individuals who perform BSE).
Time Frame: From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
Acceptability (attitude and perception of women toward BSE and satisfaction levels of the individuals who perform BSE).
The following indicators will measure this: participants' attitudes toward BSE, perception scores measured in the mean score and SD, and the percentage of women satisfied with BSE practices.
|
From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
|
Adoption
Time Frame: From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
Adoption will be measured by the percentage of CHW and FCHVs willing to adopt BSE.
It will also be measured by the extent to which FCHVs are eager and able to integrate BSE activities into their existing roles and responsibilities.
|
From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
|
Appropriateness
Time Frame: From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
Appropriateness will be measured using indicators of the extent to which CNMP is suitably suited to the cultural, social, and economic context and aligned with the needs and preferences of the target population.
|
From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
|
Feasibility of implementing FCHV induced breast-self examination
Time Frame: From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
Feasibility will be measured by assessing the practicality and ease of implementing FCHV in CNMP, quantified through the percentage of health facilities equipped with necessary resources, including training materials and equipment, as well as the proportion of FCHV implementation strategies successfully adopted
|
From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
|
Fidelity
Time Frame: From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
Fidelity will be measured by evaluating the extent to which FCHVs and HFs adhere to the prescribed guidelines and protocols for BSE screening and referral, monitoring the consistency of FCHV discussed in the HMG meeting across different communities, and evaluating the extent to which women adhere to the prescribed guidelines for BSE.
|
From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
|
Effectiveness
Time Frame: From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
Effectiveness outcomes will be measured using the following indicators: Perception, attitude, knowledge, coverage of BSE screening, and Follow-up rates for positive cases.
|
From date of randomization, baseline data collection within 2 weeks, and endline 2 months after intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bharat Kafle, Karnali Academy of Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BC2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on Implementation strategy - Health Promotion and Education-based intervention
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingLynch Syndrome | Hereditary Breast Carcinoma | Hereditary Ovarian CarcinomaUnited States
-
Rana Mohamed Ahmed FarghalCairo University; Military Medical Academy, BulgariaNot yet recruitingDental Caries | Knowledge, Attitudes, Practice | Preventive Health Care | Child Behavioral Health | Oral Health Behavior Change | Oral Hygiene, Oral HealthEgypt
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA)Not yet recruitingCigarette Smoking-Related CarcinomaUnited States
-
Marmara UniversityActive, not recruitingDiabetic Foot | Diabetes Mellitus Type 2Turkey
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States, Canada
-
University Health Network, TorontoCanadian Initiative for Outcomes in Rheumatology CareRecruiting
-
Emory UniversityCenters for Disease Control and PreventionCompletedHIV InfectionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingHuman Papillomavirus-Related CarcinomaUnited States
-
Saglik Bilimleri UniversitesiNot yet recruitingPregnant Women | Gestational Diabetes